Rethinking the course of psychotic disorders: modelling long-term symptom trajectories.

Psychotic disorder course and outcome epidemiology growth mixture models

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 5 2 2021
medline: 22 12 2022
entrez: 4 2 2021
Statut: ppublish

Résumé

The clinical course of psychotic disorders is highly variable. Typically, researchers have captured different course types using broad pre-defined categories. However, whether these adequately capture symptom trajectories of psychotic disorders has not been fully assessed. Using data from AESOP-10, we sought to identify classes of individuals with specific symptom trajectories over a 10-year follow-up using a data-driven approach. AESOP-10 is a follow-up, at 10 years, of 532 incident cases with a first episode of psychosis initially identified in south-east London and Nottingham, UK. Using extensive information on fluctuations in the presence of psychotic symptoms, we fitted growth mixture models to identify latent trajectory classes that accounted for heterogeneity in the patterns of change in psychotic symptoms over time. We had sufficient data on psychotic symptoms during the follow-up on 326 incident patients. A four-class quadratic growth mixture model identified four trajectories of psychotic symptoms: (1) remitting-improving (58.5%); (2) late decline (5.6%); (3) late improvement (5.4%); (4) persistent (30.6%). A persistent trajectory, compared with remitting-improving, was associated with gender (more men), black Caribbean ethnicity, low baseline education and high disadvantage, low premorbid IQ, a baseline diagnosis of non-affective psychosis and long DUP. Numbers were small, but there were indications that those with a late decline trajectory more closely resembled those with a persistent trajectory. Our current approach to categorising the course of psychotic disorders may misclassify patients. This may confound efforts to elucidate the predictors of long-term course and related biomarkers.

Sections du résumé

BACKGROUND
The clinical course of psychotic disorders is highly variable. Typically, researchers have captured different course types using broad pre-defined categories. However, whether these adequately capture symptom trajectories of psychotic disorders has not been fully assessed. Using data from AESOP-10, we sought to identify classes of individuals with specific symptom trajectories over a 10-year follow-up using a data-driven approach.
METHOD
AESOP-10 is a follow-up, at 10 years, of 532 incident cases with a first episode of psychosis initially identified in south-east London and Nottingham, UK. Using extensive information on fluctuations in the presence of psychotic symptoms, we fitted growth mixture models to identify latent trajectory classes that accounted for heterogeneity in the patterns of change in psychotic symptoms over time.
RESULTS
We had sufficient data on psychotic symptoms during the follow-up on 326 incident patients. A four-class quadratic growth mixture model identified four trajectories of psychotic symptoms: (1) remitting-improving (58.5%); (2) late decline (5.6%); (3) late improvement (5.4%); (4) persistent (30.6%). A persistent trajectory, compared with remitting-improving, was associated with gender (more men), black Caribbean ethnicity, low baseline education and high disadvantage, low premorbid IQ, a baseline diagnosis of non-affective psychosis and long DUP. Numbers were small, but there were indications that those with a late decline trajectory more closely resembled those with a persistent trajectory.
CONCLUSION
Our current approach to categorising the course of psychotic disorders may misclassify patients. This may confound efforts to elucidate the predictors of long-term course and related biomarkers.

Identifiants

pubmed: 33536092
doi: 10.1017/S0033291720004705
pii: S0033291720004705
pmc: PMC9647538
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2641-2650

Subventions

Organisme : MRF
ID : MRF_C0439
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0500817
Pays : United Kingdom

Auteurs

Craig Morgan (C)

ESRC Centre for Society and Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, UK.
National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.

Paola Dazzan (P)

National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, UK.

Julia Lappin (J)

Faculty of Medicine, University of New South Wales, Sydney, Australia.

Margaret Heslin (M)

King's Health Economics, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, UK.

Kim Donoghue (K)

Addictions Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, UK.

Paul Fearon (P)

Department of Psychiatry, Trinity College, Dublin, Ireland.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, UK.

Robin M Murray (RM)

National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
Psychosis Studies Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, UK.

Gillian A Doody (GA)

Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK.

Ulrich Reininghaus (U)

ESRC Centre for Society and Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, UK.
Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH